Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Brevitest is a private Houston-based diagnostics and medical device company developing portable, quantitative point-of-care testing systems that miniaturize central-lab immunoassays. Its core technology uses disposable cartridges and a compact analyzer to run automated ELISA-like assays on blood and urine samples outside traditional laboratory settings. The company initially commercialized a forensic "Liquid Autopsy" solution for rapid on-site drug-related cause-of-death assessment and has expanded the platform toward broader biomarker testing. Brevitest also describes Bioscale as an on-demand blood biomarker measurement system aimed at health, wellness, and performance monitoring. Overall, the company appears to be a platform diagnostics business focused on rapid decentralized biomarker analysis rather than a therapeutic drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Brevitest.